Zelnecirnon (RPT193) is an orally active inhibitor of CCR4 , blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues. Zelnecirnon can be used for allergic inflammation in atopic dermatitis, asthma, and other diseases research In Vitro Zelnecirnon (1 nM-10 μM) inhibits Th2 cells chemotaxis or migration with IC 50 s of ~370 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Zelnecirnon (100 mg/kg; p.o.; once daily; 2 d, 1 d before OVA-challenge) reduces skin inflammation in an acute ovalbumin (OVA)-induced atopic dermatitis model in mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Acute ovalbumin (OVA)-induced atopic dermatitis model in mouseDosage: 100 mg/kg Administration: Oral gavage; once daily; for 2 days, started 1 day before OVA-challenge (in mouse ear) Result: Decreased the ear thickness significantly. Form:Solid IC50& Target:CCR4